Rhythm Pharmaceuticals Inc Total Liabilities
Rhythm Pharmaceuticals Inc total liabilities. Based on the latest financial reports, Rhythm Pharmaceuticals Inc (RYTM) has total liabilities worth $342.12 Million USD as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check RYTM financial resilience to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Rhythm Pharmaceuticals Inc (2012–2025)
Total liabilities of Rhythm Pharmaceuticals Inc from 2012 to 2025. This chart illustrates how Rhythm Pharmaceuticals Inc's total liabilities have evolved over time, based on quarterly financial data. Explore Rhythm Pharmaceuticals Inc long-term investment intensity to see how much of total assets are deployed in long-term investments.
Rhythm Pharmaceuticals Inc Competitors by Total Liabilities
The table below lists competitors of Rhythm Pharmaceuticals Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Unigroup Guoxin Microelectronics Co Ltd
SHE:002049
|
China | CN¥5.00 Billion |
|
The Mosaic Company
NYSE:MOS
|
USA | $13.01 Billion |
|
QMMM Holdings Limited Ordinary Shares
NASDAQ:QMMM
|
USA | $71.22K |
|
Marfrig Global Foods S.A.
SA:MRFG3
|
Brazil | R$122.53 Billion |
|
MGIC Investment Corp
NYSE:MTG
|
USA | $1.51 Billion |
|
Walsin Technology Corp
TW:2492
|
Taiwan | NT$41.28 Billion |
|
Bruker Corporation
NASDAQ:BRKR
|
USA | $3.73 Billion |
|
UL Solutions Inc.
NYSE:ULS
|
USA | $1.62 Billion |
Liability Composition Analysis (2012–2025)
This chart breaks down Rhythm Pharmaceuticals Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see RYTM total assets.
Liquidity & Leverage Metrics
Rhythm Pharmaceuticals Inc Total Liabilities Ratios Explained
Rhythm Pharmaceuticals Inc total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 4.41 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 2.46 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.71 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Rhythm Pharmaceuticals Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Rhythm Pharmaceuticals Inc (2012–2025)
The table below shows the annual total liabilities of Rhythm Pharmaceuticals Inc from 2012 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $342.12 Million | +50.24% |
| 2024-12-31 | $227.72 Million | +39.72% |
| 2023-12-31 | $162.99 Million | +37.87% |
| 2022-12-31 | $118.22 Million | +160.55% |
| 2021-12-31 | $45.37 Million | +120.84% |
| 2020-12-31 | $20.55 Million | -25.30% |
| 2019-12-31 | $27.50 Million | +97.10% |
| 2018-12-31 | $13.95 Million | +100.83% |
| 2017-12-31 | $6.95 Million | +37.80% |
| 2016-12-31 | $5.04 Million | -4.40% |
| 2015-12-31 | $5.27 Million | +855.43% |
| 2014-12-31 | $552.00K | -99.27% |
| 2013-12-31 | $75.65 Million | +37.02% |
| 2012-12-31 | $55.21 Million | -- |
About Rhythm Pharmaceuticals Inc
Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases in the United States and internationally. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, … Read more